BioNJ Headlines – May 2012

BioNJ and Member Companies Advocate for Industry Issues at BIO Fly-In

BioNJ and representatives from Member Companies Amicus Therapeutics, Endo Therapeutics, Johnson & Johnson, LifeQual Pharmaceuticals, NPS Therapeutics, PTC Therapeutics, and SNR Denton walked the “Halls of Congress” to advocate for programs and policies important to the biotechnology industry during the annual BIO Fly-In to Washington, DC, on April 24-25.

More than 200 biotechnology industry representatives from 41 states participated in over 300 meetings with members of the House and Senate during the Fly-In.

The New Jersey delegation met directly on April 25 with Senator Robert Menendez and Congressmen Rush Holt, Leonard Lance, and Bill Pascrell. The delegation also held meetings with the staffs of Senator Frank Lautenberg and Congressmen Rodney Frelinghuysen, Scott Garrett, Frank LoBiondo, Steven Rothman, John Runyan, and Albio Sires. Congressman Holt and Frank Pallone also attended a BIO networking reception on April 24.

The discussions on issues critical to the biotechnology industry included:

  • Reauthorization of the Prescription Drug User Fee Act (PDUFA)
  • Proposals to accelerate the drug-approval process as proposed in the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act in the Senate and the Faster Access to Specialized Treatments (FAST) Act in the House
  • Efforts to stimulate greater antibiotic research as proposed by the Generating Antibiotic Incentives Now (GAIN) Act
  • Support for funding the National Institutes of Health at current levels.

Said Debbie Hart, President of BioNJ, “The BIO Annual Fly-In has been an important element of BioNJ’s advocacy work in our nation’s capital for a 20 years now. We appreciate the support of the Member Companies that participated in this year’s Fly-In, and we will continue to involve and inform the New Jersey community of our efforts in advocating for important issues critical to the continued success of the industry such as PDUFA, TREAT/FAST, and GAIN.

“We also very much appreciate the reception we received from our Senators and Congressmen and their staff members and their willingness to listen to our concerns.”

BREAKING NEWS: We are pleased to report that the U.S. House of Representatives approved user fee legislation (H.R. 5651) on May 30 just before Biolines began distribution. The House bill includes the reauthorization of the Prescription Drug User Fee Act (PDUFA). The House bill is similar to a bill approved last week by the Senate. BioNJ will keep you informed as the Senate and House work to reconcile the two bills.


BioNJ Helps Host Delegation from Denmark, Participates in Reception for European Union VP

BioNJ at the end of April helped to host a visit by members of the Danish financial community to the United States that included a visit to Princeton University, Insmed in Monmouth Junction, and Chromocell in North Brunswick.

Led by the Danish Nykredit, senior managers from the top 20 financial institutions in Denmark came to the United States to learn more about the health and robustness of the U.S. economic recovery and the life sciences industry. While in the United States, the delegation also visited Federal Reserve in New York, BNY Mellon, and Columbia University.

At Princeton University, the group participated in an economic briefing, which was followed by a visit to the Insmed and Chromocell labs. Thanks to the Insmed and Chromocell teams for their gracious hospitality.

The Danish government is making a concerted effort to identify and engage non-Danish companies to work with local private sector and academic entities to better leverage the country’s funding resources. In tandem, Denmark has a long tradition of biotech excellence that it wants to showcase globally through these types of outreach initiatives and potential partnering opportunities.

Danish Delegation

Members of a delegation of Danish financial institutions stopped for a moment during their tours of the laboratories at Chromocell in North Brunswick.

In other international activities, BioNJ was invited to join a high-profile, high-energy gathering of senior-level transatlantic business officials assembled at the New York Stock Exchange on May 11 to welcome visiting European Union Vice-President and Commissioner for Industry and Entrepreneurship, Antonio Tajani.

Vice-President Tajani was accompanied by a delegation of prominent European industry federations including representatives from the pharmaceutical and venture capital sectors, with the objective of internationalizing businesses in the EU and the United States. Sir Andrew Witty, CEO of Glaxo Smith Kline U.K. and concurrently the president of the European Federation of Pharmaceutical Industries and Associations (FPIA) was part of the Vice-President’s delegation, and BioNJ fully briefed him on our activities.

Vice-President Tajani directs the EU level enterprise policies, holding a wide range of responsibilities for SME and industrial innovation, regulation of manufactured goods, and standardization.

Vice-President Tajani’s visit served to foster industrial cooperation with the United States in order to support growth on both sides of the Atlantic. Prior to his New York City stop, he met senior political representatives, members of Congress, and key industry federations in Washington, DC.


BioNJ to Honor Buchanan Ingersoll & Rooney and Shareholder Linda Pissott Reig on the 5th NewX2 BioCruise

BioNJ will be pleased to honor Linda Pissott Reig, Esq., of Buchanan Ingersoll & Rooney with its Annual BioNJ Member Service Award during the fifth sailing of the NewX2 BioCruise on Wednesday, June 6, in concert with our friends at the New York Biotechnology Association (NYBA).

A strong supporter of BioNJ initiatives over the years, Linda’s strategic thinking has contributed to the development of numerous BioNJ programs, and she is also personally responsible for helping BioNJ to recruit several new Members.

Her leadership was demonstrated in her work to make the BioNJ Legal Committee a reality. As co-chair, she has pushed the Legal Committee to tackle high-level legal issues that have a direct bearing on the growth and sustainability of companies and the industry as a whole.

Also, join us as NYBA honors the founders of Regeneron Research Laboratories, Leonard S. Schleifer, MD, PhD, President and CEO, and George Yancopoulos, MD, PhD, Executive Vice-President, Chief Scientific Officer, and President, Regeneron Research Laboratories, with the “The Cures Start Here” Business Leader of the Year Award.


NewX2 BioCruise


The 5th Annual NewX2 BioCruise will bring together the biotechnology communities of New Jersey and New York for an evening of great networking, great food and great views of our two states from the mighty Hudson River.

When: Wednesday, June 6, 2012, 4:30 — 9:00 p.m.
Where: World Yacht, New York Harbor, Pier 81, Manhattan, NY
Schedule: 4:30 p.m.
5:00 p.m.

9:00 p.m.
Boarding and Registration
Cocktails and Dinner
Boarding Fees: BioNJ or NYBA Member — $160.00
Non-Member — $195.00

Click here to register!

BioNJ and NYBA thank our Sponsors.